Journal of Surgical Research
Volume 144, Issue 1 , Pages 43-48 , January 2008

Bcl-2 Gene Silencing in Pediatric Epithelial Liver Tumors

  • Steven W. Warmann, M.D.

      Affiliations

    • Department of Pediatric Surgery, University Children’s Hospital Tübingen, Tübingen, Germany
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Pediatric Surgery, University Children’s Hospital Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
    • ,
  • Heike Frank

      Affiliations

    • Department of Pediatric Surgery, University Children’s Hospital Tübingen, Tübingen, Germany
    • ,
  • Heike Heitmann

      Affiliations

    • Department of Pediatric Surgery, University Children’s Hospital Tübingen, Tübingen, Germany
    • ,
  • Peter Ruck, M.D.

      Affiliations

    • Institute of Pathology, Leonberg, Germany
    • ,
  • Tina Herberts, M.D.

      Affiliations

    • Department of Medical Biometry, University of Tübingen, Tübingen, Germany
    • ,
  • Guido Seitz, M.D.

      Affiliations

    • Department of Pediatric Surgery, University Children’s Hospital Tübingen, Tübingen, Germany
    • ,
  • Jörg Fuchs, M.D.

      Affiliations

    • Department of Pediatric Surgery, University Children’s Hospital Tübingen, Tübingen, Germany

Received 10 October 2006

References 

  1. Warmann S, Hunger M, Teichmann B, et al. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: Clinical course and in vivo model. Cancer. 2002;95:1795
  2. Bader P, Fuchs J, Wenderoth M, et al. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with Adriamycin or cisplatin. Anticancer Res. 1998;18:3127
  3. Minemura M, Tanimura H, Tabor E. Overexpression of multidrug resistance genes MDR1 and moat in human hepatocellular carcinoma and hepatoblastoma cell lines. Int J Oncol. 1999;15:559
  4. Wu Y, Li ZY, Zhao X, et al. Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2. Hum Gene Ther. 2006;17:941
  5. Warmann SW, Armeanu S, Frank H, et al. In vitro gene targeting in human hepatoblastoma. Pediatr Surg Int. 2006;22:16
  6. Zhang Y, Parker WB, Sorscher EJ, et al. PNP anticancer gene therapy. Curr Topics Med Chem. 2005;5:1259–1274
  7. Dufes C, Keith WN, Bilsland A, et al. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 2005;65:8079
  8. Fuchs U, Damm-Welk C, Borkhardt A. Silencing of disease-related genes by small interfering RNAs. Curr Mol Med. 2004;4:507
  9. Woessmann W, Damm-Welk C, Fuchs U, et al. RNA interference: New mechanisms for targeted treatment?. Rev Clin Exp Hematol. 2003;7:270
  10. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit Rev Clin Lab Sci. 2006;43:1
  11. Gardner CR. Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism. Expert Rev Anticancer Ther. 2004;4:1157
  12. Niedzielska G, Kocki J. Evaluation of bcl-2 gene expression in papilloma of larynx in children. Int J Pediatr Otorhinolaryngol. 2000;53:25
  13. Feng LF, Zhong M, Lei XY, et al. Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. J Drug Target. 2006;14:21
  14. Establishment of a cell line and its clonal sublines from a patient with hepatoblastoma Doi I. Gann. 1976;76:1
  15. Pietsch T, Fonatsch C, Albrecht S, et al. Characterization of the continuous cell line HepT1 derived from a human hepatoblastoma. Lab Invest. 1996;74:809
  16. Aden D, Fogel A, Plotkin S, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 1979;282:615
  17. Burton JD. The MTT assay to evaluate chemosensitivity. Methods Mol Med. 2005;110:69
  18. Zeitlin BD, Joo E, Dong Z, et al. Anti-angiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. Cancer Res. 2006;66:8698
  19. Nor JE, Christensen J, Liu J, et al. Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res. 2001;61:2183
  20. Karl E, Warner K, Zeitlin B, et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res. 2005;65:5063
  21. Deng X, Gao F, Flagg T, et al. Bcl2’s flexible loop domain regulates p53 binding and survival. Moll Cell Biol. 2006;26:4421
  22. Gray SG, Hartmann W, Eriksson T, et al. Expression of genes involved with cell cycle control, cell growth, and chromatin modification are altered in hepatoblastomas. Int J Mol Med. 2000;6:161
  23. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res. 2000;6:2547
  24. Yamanaka K, Rocchi P, Miyake H, et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther. 2005;4:1689
  25. Milella M, Trisciuoglio D, Bruno T, et al. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells. Clin Cancer Res. 2004;10:7747
  26. Fu GF, Lin XH, Han QW, et al. RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol Ther. 2005;4:822
  27. Ocker M, Neureiter D, Lueders M, et al. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut. 2005;54:1298
  28. Manka D, Spicer Z, Millhorn DE. Bcl-2/adenovirus E1B 19 kDa interacting protein-3 knockdown enables growth of breast cancer metastases in the lung, liver, and bone. Cancer Res. 2005;65:11689
  29. Haberle B, Bode U, von Schweinitz D. Differentiated treatment protocols for high- and standard-risk hepatoblastoma—an interim report of the German Liver Tumor Study HB99. Klin Padiatr. 2003;215:159
  30. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma (Final report of the second study of the International Society of Pediatric Oncology SIOPEL-2). Eur J Cancer. 2004;40:411
  31. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000;18:2665
  32. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: A Pediatric Oncology Group Phase II study. J Clin Oncol. 2002;20:3438
  33. Kiani B, Ferrell LD, Qualman S, et al. Immunohistochemical analysis of embryonal sarcoma of the liver. Appl Immunohistochem Mol Morphol. 2006;14:193
  34. Ikeguchi M, Hirooka Y, Kaibara N. Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma. Cancer. 2002;95:1938
  35. Warmann S, Gohring G, Teichmann B, et al. P-glycoprotein improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res. 2003;23:4607
  36. Alshatwi AA, Han CT, Schoene NW, et al. Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells. Exp Biol Med. 2006;231:611
  37. Baldini PM, De Vito P, Antenucci D, et al. Atrial natriuretic peptide induces cell death in human hepatoblastoma (HepG2) through the involvement of NADPH oxidase. Cell Death Differ. 2004;2(Suppl.11):S210
  38. Brandt S, Heller H, Schuster KD, et al. The tamoxifen-induced suppression of telomerase activity in the human hepatoblastoma cell lie HepG2: A result of post-translational regulation. J. Cancer Res Clin Oncol. 2005;131:120
  39. Kern MA, Haugg AM, Koch AF, et al. Cyclo-oxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res. 2006;66:7059
  40. Cho-Rok J, Yoo J, Jang YJ, et al. Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology. 2006;43:1042
  41. Huang SL, Wu Y, Yu H, et al. Inhibition of Bcl-2 expression by a novel tumor-specific RNA interference system increases chemosensitivity to 5-fluorouracil in HeLa cells. Acta Pharmacol Sin. 2006;27:242
  42. Sangkhathat S, Kusafuka T, Miao J, et al. In vitro RNA interference against β-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol. 2006;28:715
  43. Koch A, Weber N, Waha A, et al. Mutations and elevated transcriptional activity of conducting (AXIN2) in hepatoblastomas. J Pathol. 2004;204:546
  44. Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the β-catenin gene. Cancer Res. 1999;59:269–273

PII: S0022-4804(07)00189-8

doi: 10.1016/j.jss.2007.03.054

Journal of Surgical Research
Volume 144, Issue 1 , Pages 43-48 , January 2008

Article Tools

* Image Usage & Resolution